Free Trial
NASDAQ:INCR

InterCure 4/30/2026 Earnings Report

InterCure logo
$0.84 +0.02 (+2.43%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

InterCure EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

InterCure Revenue Results

Actual Revenue
$23.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InterCure Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

InterCure Earnings Headlines

Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
See More InterCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InterCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InterCure and other key companies, straight to your email.

About InterCure

InterCure (NASDAQ:INCR) Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives. The company’s in-house R&D team works in collaboration with academic and medical institutions to explore novel therapeutic applications of cannabinoids. InterCure’s product portfolio includes standardized oils, capsules and topical formulations designed to address specific clinical indications and patient preferences.

Beyond its domestic footprint, InterCure has entered strategic partnerships aimed at exporting medical cannabis products to select European and Latin American markets. These collaborations are structured to meet local regulatory requirements and quality standards, offering a pathway for InterCure’s intellectual property and high-potency strains to reach new patient populations.

Looking forward, InterCure is focused on scaling its production capacity, enhancing process efficiencies and expanding its international presence through licensing agreements and joint ventures. The company continues to invest in clinical research, advanced processing technologies and new product development as it seeks to establish a broader footprint in the evolving global medical cannabis industry.

View InterCure Profile